Tag: cancer

Tax filings reveal Biden cancer charity spent millions on salaries, zero on research

A cancer charity started by Joe Biden gave out no money to research, and spent most of its contributions on staff salaries, federal filings show.

The Biden Cancer Initiative was founded in 2017 by the former vice president and his wife Jill Biden to “develop and drive implementation of solutions to accelerate progress in cancer prevention, detection, diagnosis, research and care and to reduce disparities in cancer outcomes,” according to its IRS mission statement. But it gave out no grants in its first two years, and spent millions on the salaries of former Washington DC aides it hired.

The charity took in $4,809,619 in contributions in fiscal years 2017 and 2018, and spent $3,070,301 on payroll in those two years. The group’s president, Gregory Simon, raked in $429,850 in fiscal 2018 (July 1, 2018 to June 30, 2019), according to the charity’s most recent federal tax filings.

Keep reading

Repurposing Drugs in Oncology (ReDO)—chloroquine and hydroxychloroquine as anti-cancer agents

Chloroquine (CQ) and hydroxychloroquine (HCQ) are well-known 4-aminoquinoline antimalarial agents. Scientific evidence also supports the use of CQ and HCQ in the treatment of cancer. Overall, preclinical studies support CQ and HCQ use in anti-cancer therapy, especially in combination with conventional anti-cancer treatments since they are able to sensitise tumour cells to a variety of drugs, potentiating the therapeutic activity. Thus far, clinical results are mostly in favour of the repurposing of CQ. However, over 30 clinical studies are still evaluating the activity of both CQ and HCQ in different cancer types and in combination with various standard treatments. Interestingly, CQ and HCQ exert effects both on cancer cells and on the tumour microenvironment. In addition to inhibition of the autophagic flux, which is the most studied anti-cancer effect of CQ and HCQ, these drugs affect the Toll-like receptor 9, p53 and CXCR4-CXCL12 pathway in cancer cells. In the tumour stroma, CQ was shown to affect the tumour vasculature, cancer-associated fibroblasts and the immune system. The evidence reviewed in this paper indicates that both CQ and HCQ deserve further clinical investigations in several cancer types. Special attention about the drug (CQ versus HCQ), the dose and the schedule of administration should be taken in the design of new trials.

Keep reading